Endometrial cancer (EC) is one of the most common gynecologic malignant tumors increasing investment for research to find more effective therapeutic strategies. These trials target different mechanisms of disease and various therapeutic strategies in the context of endometrial cancer pathobiology. The analysis outlines the two main mechanisms and drugs in development for each category including a total number of trials focusing on them.
The following table outlines the primary mechanisms of action being investigated in endometrial cancer clinical trials, highlighting the associated drugs and the number of trials focused on each therapeutic approach.
|
Mechanism of Action |
Key Drugs |
|---|---|
|
Immune Checkpoint Inhibition |
Pembrolizumab, Dostarlimab, Nivolumab |
|
PI3K/AKT/mTOR Pathway Inhibition |
Everolimus, Alpelisib, Temsirolimus |
|
Hormonal Therapy |
Letrozole, Megestrol Acetate, Tamoxifen |
|
Anti-VEGF Therapy (Angiogenesis Inhibition) |
Bevacizumab, Aflibercept |
|
HER2/neu Inhibition |
Trastuzumab, Lapatinib |
|
PARP Inhibition |
Olaparib, Niraparib |
|
Targeting Mismatch Repair Deficiency (dMMR) and MSI-H |
Pembrolizumab, Dostarlimab |
Immune Checkpoint Inhibition (140 Trials): Immune checkpoint inhibitors, such as Pembrolizumab, Dostarlimab, and Nivolumab, are the most explored drugs in endometrial cancer trials. By inhibiting the PD-1/PD-L1 interaction, these therapies reactivate an immune response to recognize and kill cancer cells, providing a particular benefit in tumors with high mutation loads or microsatellite instability.
PI3K/AKT/mTOR Pathway Inhibition (85 Trials): The PI3K/AKT/mTOR pathway, which is frequently activated in EC and functions to promote tumor growth and survival. Having identified the relevant pathway, drugs such as Everolimus and Alpelisib are being trialled in order to inhibit it with a hope of slowing down or stopping its progress.
Hormonal Therapy (70 Trials): These include hormonal therapies as letrozole, megestroleacetate and tamoxifen in hormone receptor positiveedometrial cancers. These therapies decrease the amounts of estrogen in the body or block estrogen receptors, which decreases how fast hormone-driven cancers grow.
Anti-VEGF Therapy (Angiogenesis Inhibition) (60 Trials): Bevacizumab and Aflibercept are antiangiogenic drugs that target VEGF pathways to reduce blood supply of tumors, necessary for their growth & metastasis.
HER2/neu Inhibition (45 Trials): A subset of endometrial cancers overexpress the HER2/neu protein, and drugs like Trastuzumab and Lapatinib target this receptor to inhibit tumor growth.
PARP Inhibition (50 Trials): PARP inhibitors, e.g., Olaparib and Niraparib target DNA repair mechanisms making these agents especially active in cancers with homologous recombinant mutation deficiency such as those seen with BRCA mutations.
Targeting Mismatch Repair Deficiency (dMMR) and MSI-H (100 Trials): Tumor-encoded mismatch repair deficiency/microsatellite instability-high status predicts response to immunotherapy by an anti-tumor immune mechanism. Keytruda and Jemperli have established medications at this level, exploiting the high mutation burden in drivers of immune enhancement.
The clinical trials landscape for endometrial cancer illustrates the trend toward precision medicine, with an increasing proportion of new drugs — in all phases of testing — targeting molecular and genetic features of tumors. These include immune checkpoint inhibitors and PI 3-kinase/AKT/mTOR pathway inhibitors, underscoring efforts to target the major biology driving carcinogenesis.
The results of these trials may in the future shape treatment guidelines, especially as more data is accumulating that demonstrates some targeted therapies work better for certain subpopulations of patients with endometrial cancer. Together, the geographic distribution and number of trials demonstrated worldwide investment in developing treatments for endometrial cancer with potential regulatory approval processes as well market dynamics.
Table of Contents
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3.1 Top-Down Approach
3.2 Bottom-Up Approach
3.3 Data Validation
3.4 Primary Interviews
4.1 Overview of Ongoing Clinical Trials
4.2 Geographical Distribution of Research Efforts
5.1 Detailed Country-wise Breakdown of Ongoing Trials
5.2 Comparative Analysis and Global Hotspots for Endometrial Cancer Research
6.1 Profiles of Top Drugs in Current Clinical Trials
6.2 Analysis of Drug Efficacy and Safety Based on Current Data
7.1 Detailed Analysis of Trials Focusing on Hormone-Receptor Positive and HER2-positive Cancers
7.2 Trends and Outcomes in Targeting Specific Subtypes
8.1 Phase-wise Distribution of Ongoing Trials
8.2 Insights into Progression and Focus of Research Across Different Phases
9.1 Overview of Global Regulatory Frameworks Affecting Clinical Trials
9.2 Impact of Regulations on Trial Designs and Market Entry
10.1 Market Size and Forecast (2022-2032)
10.2 Impact of Clinical Trial Outcomes on Market Dynamics
11.1 Predictive Analysis Based on Current Trials and Historical Data
11.2 Potential Future Trends and Breakthroughs in Treatment
12.1 Insights for Stakeholders in the Pharmaceutical and Healthcare Sectors
12.2 Recommendations Based on Current Trends and Market Needs
13.1 Glossary of Terms
13.2 List of Abbreviations
13.3 References and Data Sources
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
